- Home
- HNVR vs IPHA Comparison
HNVR vs IPHA Comparison
Compare HNVR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- IPHA
- Stock Information
- Founded
- HNVR 2008
- IPHA 1999
- Country
- HNVR United States
- IPHA France
- Employees
- HNVR N/A
- IPHA N/A
- Industry
- HNVR Commercial Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- IPHA Health Care
- Exchange
- HNVR Nasdaq
- IPHA Nasdaq
- Market Cap
- HNVR 143.6M
- IPHA 160.1M
- IPO Year
- HNVR 2022
- IPHA 2019
- Fundamental
- Price
- HNVR $23.11
- IPHA $2.44
- Analyst Decision
- HNVR Buy
- IPHA Strong Buy
- Analyst Count
- HNVR 1
- IPHA 1
- Target Price
- HNVR $22.00
- IPHA $11.00
- AVG Volume (30 Days)
- HNVR 27.4K
- IPHA 33.6K
- Earning Date
- HNVR 04-23-2025
- IPHA 03-27-2025
- Dividend Yield
- HNVR 1.73%
- IPHA N/A
- EPS Growth
- HNVR N/A
- IPHA N/A
- EPS
- HNVR 1.30
- IPHA N/A
- Revenue
- HNVR $65,041,000.00
- IPHA $20,831,349.00
- Revenue This Year
- HNVR N/A
- IPHA $209.83
- Revenue Next Year
- HNVR $15.80
- IPHA $83.96
- P/E Ratio
- HNVR $17.77
- IPHA N/A
- Revenue Growth
- HNVR 1.13
- IPHA N/A
- 52 Week Low
- HNVR $15.92
- IPHA $1.29
- 52 Week High
- HNVR $27.14
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- HNVR 56.86
- IPHA 73.73
- Support Level
- HNVR $22.37
- IPHA $2.22
- Resistance Level
- HNVR $23.94
- IPHA $2.34
- Average True Range (ATR)
- HNVR 0.77
- IPHA 0.15
- MACD
- HNVR 0.12
- IPHA 0.04
- Stochastic Oscillator
- HNVR 74.93
- IPHA 84.40
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.